V. Pete Yeung

Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors

K. Morrissey, F. Cattaruzza, Milton To, 2023, Nature Cancer.